“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 25/03/2023
EUR2.15
▲ −0.04 (−1.83%)
Market capitalisation
EUR125m
Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer and neuroendocrine tumours. Vafidemstat, its central nervous system asset, has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is now the lead study.
Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and potentially a favourable safety/efficacy profile than the first generation HDAC inhibitors.
Managing Director - Head of Content, Healthcare
Carlos Buesa
CEO
Forecast net debt (€m)
5.2
Forecast gearing ratio (%)
8
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (12.6) | (17.9) | (24.0) |
| Relative | (11.0) | (24.7) | (28.4) |
| 52 week high/low | €3.0/€2.1 |
Oryzon Genomics has announced it has enrolled the first patient in its Phase Ib FRIDA study investigating iadademstat in combination with Astellas’ FDA-approved FLT3 inhibitor gilteritinib to treat FLT3+ relapsed/refractory (r/r) acute myeloid leukaemia (AML) patients. The FRIDA study is central to Oryzon’s overall strategy as management believes the second-line AML setting may represent a potentially quicker route to market for iadademstat, targeting an AML patient population with limited and sub-optimal treatment options. FRIDA will recruit up to 45 patients across 10–15 trial sites in the United States and, in our view, its initiation marks a significant clinical milestone for the company.
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 10.6 | (6.9) | (7.2) | (8.83) | N/A | N/A |
| 2022A | 15.7 | (5.3) | (6.4) | (7.43) | N/A | N/A |
| 2023E | 17.3 | (3.7) | (4.2) | (3.31) | N/A | N/A |
| 2024E | 19.0 | (9.3) | (10.0) | (13.79) | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
